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We have previously identified UMP-CMP kinase (CMPK1) as a prognostic marker for triple negative 
breast cancer (TNBC) by mass spectrometry (MS). In this study we evaluated CMPK1 association to 
prognosis in an independent set of samples by immunohistochemistry (IHC) and assessed biological 
pathways associated to its expression through gene set enrichment analysis (GSEA). A total of 
461 TNBC paraffin-embedded tissues were collected from different academic hospitals in Europe, 
incorporated into tissue micro-arrays (TMA), and stained for CMPK1 expression. We also collected 
gene expression data of 60 samples, which were also present in the TMA, for GSEA correlation analysis. 
CMPK1 IHC staining showed both cytoplasmic and nuclear components. While cytoplasmic CMPK1 
did not show any association to metastasis free survival (MFS), nuclear CMPK1 was associated to poor 
prognosis independently from other prognostic factors in stratified Cox regression analyses. GSEA 
correlation analysis of the nuclear CMPK1-stratified gene expression dataset showed a significant 
enrichment of extracellular matrix (ECM; positive correlation) and cell cycle (negative correlation) 
associated genes. We have shown here that nuclear CMPK1 is indicative of poor prognosis in TNBCs and 
that its expression may be related to dysregulation of ECM and cell cycle molecules.
TNBC is a subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (Her2)1. Patients diagnosed with TNBC generally manifest 
adverse clinical outcome when compared to other breast cancer subtypes and, to date, there is no clinically avail-
able targeted therapy for these patients2. In this perspective, the majority of TNBC patients receive adjuvant 
chemotherapy after resection of the primary tumor. Recently, we identified an 11-protein signature that predicts 
prognosis of TNBC patients by using laser capture microdissection coupled to high resolution MS analysis3. 
While this signature displayed high sensitivity and specificity for predicting disease outcome, introduction of a 
proteomic workflow as the one used to develop our classifier4 into a clinical setting is not yet feasible due to exten-
sive sample preparation and measurement times. In this perspective, an immuno-based (e.g. IHC) assay would 
constitute a suitable approach to application in clinical diagnostics. CMPK1, as part of the 11-protein signature, 
was identified as a prognostic marker for lymph-node negative (LNN) and adjuvant systemic chemotherapy naive 
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(ASCN) TNBC patients. In the current study, we used a TMA platform to further investigate the clinical signifi-
cance of CMPK1 in TNBC patients.
CMPK1 is a 22 kDa enzyme that catalyzes phosphorylation of pyrimidine nucleoside monophosphates, which 
is essential for de novo biosynthesis of pyrimidines5,6. Also, CMPK1 performs a crucial role in activation of nucle-
oside analogues used as chemotherapy against human cancers and pathogenic viruses7. In a neoplastic setting, 
decreased expression of CMPK1 mRNA has been associated with 5-fluorouracil resistance of a colorectal cancer 
cell line HCT-88. Some genetic polymorphisms of CMPK1 have also been reported as a prognostic marker for 
non-small cell lung cancer9 and pancreatic cancer10 patients treated with a gemcitabine-based chemotherapy. 
CMPK1 has been observed in different subcellular locations of HeLa S3 cancer cells, as it predominantly localizes 
in the cytoplasm but can also enter the nucleus6. Subcellular localization of this protein may be important for 
cancer progression, but no study has yet revealed whether this has prognostic or predictive value in breast cancer. 
Therefore, further investigation may help to understand the clinical value of this marker, including its subcellular 
localization.
In this study, we evaluated whether CMPK1 expression in different subcellular compartments is associated to 
patient prognosis in TNBC patients by IHC analysis of TMA derived from different academic medical centers in 
Europe. In order to elucidate the molecular pathways associated to subcellular localization of CMPK1, we per-
formed GSEA correlation analysis on a subset of tumors incorporated in the TMA, of which gene expression data 
was available. A schematic representation of this workflow is shown in Fig. 1.
Results
Expression and subcellular localization of CMPK1 in triple negative breast cancer tissues. 
Analysis of the staining results of an anti-CMPK1 antibody on breast tissues showed that CMPK1 prevalently 
stained epithelial cells of the mammary gland (normal cells: Fig. S1; carcinoma cells: Fig. S2A–D). When analyz-
ing breast carcinoma tissues, both nuclear and cytoplasmic localization of CMPK1 protein was observed, as pre-
viously described in cancer cell lines6. Cytoplasmic CMPK1 (cCMPK1) was generally ubiquitous, as the majority 
of tissues (80.2%) expressed cCMPK1 in more (> ) than 70% of carcinoma. Regarding intensity distribution, only 
a small percentage (9.5%) of tissues was found negative or showed a faint staining (7.0%), while most tissues dis-
played either weak (33.3%) or moderate (35.5%) cCMPK1 staining. Only 14.7% of cores showed strong cCMPK1 
staining intensity (Fig. S2E–F).
On the other hand, nuclear CMPK1 (nCMPK1) staining showed differences in terms of quantity of stained 
carcinoma cells and staining intensity. Nearly a third (29.7%) of cores did not show any nCMPK1 staining, while 
positive tissues displayed large heterogeneity in the number of stained tumor cells: 10.6% of tissues showed stain-
ing in 1–10% of tumor cells, while 12.8% and 17.2% displayed a number of stained carcinoma cells between 
11–25% and 26–50%, respectively. One third (i.e. 29.7%) of tissue cores showed nCMPK1 staining in more than 
50% of carcinoma cells (8.8% and 20.9% of the tumors showed expression in 51–70% and > 70% of the tumor 
cells, respectively; Fig. S2E). When assessing nCMPK1 staining intensity distribution, the majority of positive tis-
sues showed weak (16.5%), moderate (23.4%) and strong (24.5%) stainings, with only a small percentage (5.9%) 
showing faint staining (Fig. S2F). Overall these data show that, while cCMPK1 presents a generally ubiquitous 
and homogeneous staining, nCMPK1 staining varies widely in terms of stained tumor cells and staining intensity.
Differences between the TMA datasets. We next compared the three TMA datasets with respect to pos-
sible differences in clinical and histopathological parameters (Table 1). The RUMC and CUH cohorts comprised 
Figure 1. Schematic representation of experimental workflow. 
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a higher number of postmenopausal women (χ 2 test P < 0.001; Fig. S3A) and a higher median age at diagnosis 
when compared to the EMC cohort (Kruskal-Wallis test P < 0.001; Fig. S3B). There were no differences in patho-
logical tumor size (pT) between the three patient groups (χ 2 test P = 0.085; Fig. S3C). The EMC patient set had 
relatively more poor grade tumors (Bloom-Richardson grading score11; χ 2 test P < 0.001; Fig. S3D), and con-
tained a higher number of lymph node positive patients (χ 2 test P < 0.001; Fig. S3E). Due to the fact that both the 
RUMC and the CUH cohorts had small numbers of patient samples compared with EMC, we combined the three 
sets, which skewed the aforementioned observed differences (Table 1).
Association of CMPK1 subcellular localization to MFS. In order to assess whether nuclear and cyto-
plasmic CMPK1 stainings measured by IHC were associated to our previous MS findings, a total of 29 samples 
overlapping with both our TMA and MS sets were analyzed by correlation analysis. No significant correlation was 
found between cytoplasmic (Spearman r = 0.24; P = 0.210; Fig. S4A) or nuclear (Spearman r = − 0.04; P = 0.824; 
Fig. S4B) CMPK1 stainings and MS-derived intensity. Taken together, these data support that nCMKP1 nor 
cCMPK1 analyzed by IHC do not directly relate to total CMPK1 levels measured by high resolution MS.
We next evaluated the prognostic value as a function of both cytoplasmic and nuclear CMPK1 staining. In 
order to rule out any potential remaining biases due to tissue set of origin, all Cox regression models were strat-
ified according to hospital of origin12. Furthermore, for both cytoplasmic and nuclear components of CMPK1 
staining, we derived a ‘histo-score’ (see Methods), which resulted from the combination of intensity and quantity 
categories (histo-score range: 0–20; Table S1). In our stratified Cox regression analyses, patients were stratified 
based on 4 histo-score categories: 0–5; 6–10; 11–15, and 16–20.
We first analyzed systemic treatment (chemotherapy) naïve patients with LNN disease only (n = 273; Table 1) 
to reveal the pure prognostic value of nuclear and cytoplasmic CMPK1. Log-rank test for trend and stratified Cox 
regression analyses showed that cCMPK1 staining (Fig. S5A–D) was not associated to MFS (Fig. S5E and Table S2). 
On the other hand, nCMPK1 levels (Fig. 2A–D) were significantly associated with a poor MFS (Fig. 2E) in both 
univariate and multivariate stratified Cox regression analyses (Table 2). In all Cox models (i.e. univariate and mul-
tivariate regression analyses for cCMPK1 and nCMPK1) age, menopausal status, tumor size and differentiation 
did not show any significant association to MFS.
Having established that nCMPK1 is significantly associated to poor prognosis in treatment naïve patients with 
LNN disease, we then tested whether chemotherapy treatment influenced the prognostic impact of nCMPK1 as 
CMPK1 has been connected to chemotherapy response. Importantly, nCMPK1 levels measured by histo-score 
showed no significant difference between chemotherapy treated and untreated patients (Mann-Whitney 
P = 0.598; Fig. S6). Subsequently, we extended our stratified Cox regression analyses to assess the prognostic 
  RUMC* CUH* EMC* Total*
Total n of patients 48 (100.0) 83 (100.0) 267 (100.0) 398 (100.0)
Age (years)
 ≤ 40 7 (14.6) 12 (14.5) 65 (24.3) 84 (21.1)
 41–55 18 (37.5) 22 (26.5) 113 (42.3) 153 (38.4)
 56–70 19 (39.6) 29 (34.9) 67 (25.1) 115 (28.9)
 > 70 4 (8.3) 20 (24.1) 22 (8.3) 46 (11.6)
Menopausal status
 Premenopausal 18 (37.5) 24 (28.9) 155 (58.0) 197 (49.5)
 Postmenopausal 30 (62.5) 59 (71.1) 112 (42.0) 201 (50.5)
Tumor size
 pT1 22 (45.8) 49 (59.1) 107 (40.1) 178 (44.7)
 pT2 + pTx 24 (50.0) 30 (36.1) 147 (55.0) 201 (50.5)
 pT3 + pT4 2 (4.2) 4 (4.8) 13 (4.9) 19 (4.8)
Tumor Grade
 Good 0 (0.0) 2 (2.4) 4 (1.5) 6 (1.5)
 Moderate 5 (10.4) 8 (9.6) 44 (16.5) 57 (14.3)
 Poor 32 (66.7) 54 (65.1) 213 (79.8) 299 (75.1)
 Unknown 11 (22.9) 19 (22.9) 6 (2.2) 36 (9.1)
Lymph node positivity
 0 46 (95.8) 83 (100.0) 202 (75.6) 331 (83.2)
 1 to 3 2 (4.2) 0 (0.0) 44 (16.5) 46 (11.6)
 > 3 0 (0.0) 0 (0.0) 21 (7.9) 21 (5.2)
Adjuvant chemotherapy
 Yes 2 (4.2) 40 (48.2) 83 (31.1) 125 (31.4)
 No 46 (95.8) 43 (51.8) 184 (68.9) 273 (68.6)
Table 1.  Clinical and histopathological characteristics of patients included in the TMAs. *Data are 
displayed as number (percentage). Acronyms: CUH: Copenhagen University Hospital; EMC: Erasmus 
University Medical Center; RUMC: Radboud University Medical Center.
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Figure 2. Prognostic significance of nuclear CMPK1 staining. Panels A–D shows breast cancer tissue cores 
displaying the four nCMPK1 histo-score categories (categories: 0–5, 6–10, 11–15, and 16–20). Kaplan-Meier 
curves were plotted for each category and Log-rank test for trend was performed (E). Acronyms: HR: Hazard 
Ratio; CI: Confidence Interval.
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value of nCMPK1 in our entire TMA cohort by including chemotherapy treated patients (n = 125; n total = 398). 
Our analyses showed that, while no significant association between adjuvant chemotherapy treatment and MFS 
was found, nCMPK1 remained a significant prognostic factor (Fig. S7 and Table S3).
Analysis of gene expression data associated to nuclear CMPK1 expression. Having established 
that only nCMPK1 is related to prognosis in TNBC patients, we sought to elucidate which genes in the entire 
transcriptome were associated to its expression in order to reveal the putative shared biology with nCMPK1. 
For this, we collected gene expression data from our previously published dataset13 (Gene Expression Omnibus 
[GEO] ID: GSE2034), and selected samples which overlapped with our TMA cohort (n = 60, n of genes = 10,520). 
Transcriptome and nCMPK1 histo-scores in the 60 matching samples were correlated by GSEA analysis. We iden-
tified that ‘extracellular matrix (ECM) organization’ and ‘DNA replication/cell cycle’ related pathways as the most 
significant gene sets positively and negatively associated with the nCMPK1 expression, respectively (Fig. 3A). 
For instance, the ‘core matrisome’ and ‘ECM glycoproteins’ showed the most significant positive correlation with 
nCMPK1 histo-scores, and we could clearly observe an increased expression of the ‘core matrisome’ genes in the 
tumors with higher nCMPK1 expression (Fig. 3B, upper panel). Oppositely, the ‘DNA replication’ and ‘mitotic 
M-M/G1’ genes were the most significant gene sets negatively correlated with nCMPK1 expression, and higher 
expression of the ‘DNA replication’ genes were observed in the tumors with less nCMPK1 expression (Fig. 3B, 
lower panel). Taken together, these data indicate that nCMPK1 levels are associated to ECM and cell cycle related 
molecules.
Discussion
The predictive and prognostic value of CMPK1 mRNA expression and genetic polymorphisms have been 
described in colorectal tumors8, non-small cell lung carcinoma9, and pancreatic cancer patients who received 
pyrimidine nucleoside analogue-based chemotherapies as first line treatment10. Also, CMPK1 has been shown 
to localize both in the nucleus and cytoplasm of cancer cells6, though the clinical relationship of this finding in 
TNBC has not been investigated. In the current study, we have investigated the association of CMPK1 subcellular 
localization with prognosis in TNBC patients.
IHC staining of TNBC tissues included in a TMA showed that CMPK1 was expressed both in the nucleus 
as well as in the cytoplasm of breast carcinoma cells, as it was also discovered for another marker (i.e. FTH1) 
belonging to the same signature3,14. While the cytoplasmic component appeared to be ubiquitous and homoge-
neous, as staining intensity was generally weak or moderate and present in the majority (> 70%) of tumor cells, 
nCMPK1 displayed a higher degree of heterogeneity in terms of expression and number of stained tumor cells. 
The assessment of the clinical relevance of both cCMPK1 and nCMPK1 expression (derived from histo-score 
calculations) using stratified Cox regression models showed that cCMPK1 levels were not associated with prog-
nosis of TNBCs, probably due to its ubiquitous expression in breast carcinomas included in the TMA. On the 
n of patients
Univariate Multivariate
HR 95% CI P HR 95% CI P
nCMPK1 histo-score
 0–5 133 1.00 1.00
 6–10 57 2.26 1.22 to 4.20 0.009 2.46 1.30 to 4.66 0.006
 11–15 39 1.98 0.99 to 3.96 0.054 1.91 0.90 to 4.06 0.090
 16–20 44 2.74 1.48 to 5.07 0.001 2.66 1.39 to 5.08 0.003
Age (years)
 < 40 51 1.00 1.00
 41–55 86 0.86 0.48 to 1.56 0.634 0.89 0.46 to 1.70 0.724
 56–70 90 0.82 0.45 to 1.48 0.511 1.05 0.36 to 3.10 0.921
 > 70 46 0.46 0.17 to 1.25 0.130 0.51 0.13 to 1.98 0.330
Menopausal status
 Premenopausal 115 1.00 1.00
 Postmenopausal 158 0.74 0.47 to 1.18 0.213 0.86 0.35 to 2.14 0.747
Tumor size
 pT1 119 1.00 1.00
 pT2 + pTx 143 1.11 0.70 to 1.76 0.665 1.35 0.82 to 2.21 0.238
 pT3 + pT4 11 0.51 0.07 to 3.78 0.515 0.83 0.11 to 6.34 0.861
Tumor Grade
 Good 3 1.00 1.00
 Moderate 38 0.48 0.11 to 2.11 0.329 0.42 0.08 to 2.16 0.299
 Poor 206 0.29 0.07 to 1.19 0.087 0.31 0.06 to 1.53 0.152
 Unknown 26 0.15 0.02 to 1.13 0.066 0.12 0.01 to 0.99 0.049
Table 2.  Stratified Cox regression analyses for the association of nCMPK1 to MFS in lymph-node negative 
and adjuvant therapy naïve patients. Acronyms: CI: confidence interval; HR: hazard ratio.
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other hand, nCMPK1 expression was found significantly associated with poor prognosis. In fact, we not only 
established that nCMPK1 is indicative of poor prognosis in a chemotherapy untreated group, thus reflecting the 
natural course of the disease (i.e. LNN and chemotherapy naive), but we also showed that the prognostic power is 
Figure 3. Nuclear CMPK1 (nCMPK1) associated canonical pathways. Panel A displays the summary of top 
10 canonical pathways positively (left panel) and negatively (right panel) correlated to nCMPK1 expression 
(CHON_DERM_METABOLISM: chondroitin sulfate dermatan sulfate metabolism, NES: normalized 
enrichment score). Panel B displays examples of the pathways associated with nCMPK1 expression. Left panel: 
enrichment plots of the most significant pathways; Middle panel: heatmaps of the significant genes in ‘core 
matrisome’ and ‘DNA replication’ pathways; Right panel: expression of the heatmap genes in 4 groups based on 
nCMPK1 expression.
www.nature.com/scientificreports/
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independent of clinical and histopathological factors such as age, menopausal status, tumor size, grade, presence 
of lymph node metastases and adjuvant chemotherapy treatment. Furthermore, the fact that nCMPK1 is associ-
ated to poor prognosis, opposite of what has been shown for total CMPK1 expression as measured by MS, may 
indicate a differential role for this kinase depending on its subcellular localization. This apparent discrepancy with 
our previous MS-based findings may be due to the fact that cCMPK1 staining, as represented in the majority of 
IHC stained tumor cells, likely better represented the total CMPK1 expression as measured by MS in our previous 
study, though no correlation between any IHC CMPK1 stainings and MS data was found. This may be ascribed to 
the fact that, on one hand, MS provided an accurate quantitative measure of protein levels but cannot differentiate 
between nuclear and cytoplasmic CMPK1. On the other hand, IHC is a semi-quantitative technique that cannot 
very accurately assess target protein levels due to limitations in chromogenic signal quantification, as it has also 
been reported for other (breast cancer) markers15.
After having established clinical significance for nCMPK1 in TNBC, we explored the biology correlated to 
nCMPK1 expression through pathway analysis on a subset of samples for which both gene expression and IHC 
data were available. CMPK1 is involved in cytidine metabolism and incorporation during DNA replication. Two 
recent studies have shown that CMPK1 is crucial for the incorporation of deoxycytidine (dC), and prevents the 
introduction of modified cytosines (5-methyl-2′ deoxycytidine/5mdC, 5-hydroxymethyl-2′ deoxycytidine/5hmdC 
and 5-formy-2′ deoxycytidine/5fdC) during the DNA replication process16. Correct dC integration prevents oxi-
dative damage on the DNA of tumor cells introduced by incorporation of 5hmdC and is therefore essential to 
maintain genomic integrity during the normal cell cycle. In line with this mechanism, in the current study we 
identified nCMPK1 as a negative cell cycle regulator. This observation is contradictive in respect to the knowledge 
that fast cell cycle allows high proliferation and tumor malignancy. However, nCMPK1 may contribute to cancer 
cell survival and malignancy in a unique manner: Oxidative stress, as a hallmark for cancer17, causes accumu-
lation of modified cytotoxic cytosines in tumor cells, which can be integrated into DNA replication by cytidine 
deaminase (CDA). The nCMPK1 components block the incorporation path of the modified cytosines and only 
allows dC incorporation during DNA replication16. Therefore, increased nCMPK1 may force the cell into a dC 
incorporation flux while, at the same time, slows down the cell cycle and consequently reduces the incorporation 
rate of modified cytosines caused by rapid cell cycling. On the other hand, oxidative stress results in alteration 
of tumor microenvironment, which contributes to the reorganization of the extracellular matrix (ECM) and 
provides a favorable metastatic environment for the tumor cells18. Hence, it is not unexpected that the gene sets 
related to ECM organization were positively associated with nCMPK1 expression.
In conclusion, we report that nuclear expression of CMPK1, as measured by IHC, is associated with poor 
prognosis in TNBC independently of clinical and histopathological factors, and it is associated to ECM and cell 
cycle molecules dysregulation. Further studies are needed though to establish the causality between these mech-
anisms and to possibly derive new therapeutic targets.
Methods
Primary breast cancer tissues. A total of 627 primary breast cancer tissues were collected from Erasmus 
Medical Center (EMC; n = 412), Radboud University Medical Center (RUMC; n = 129), and Copenhagen 
University Hospital (CUH; n = 86), and were used to construct three separate TMAs. Expression of ER, PR and 
Her2 proteins was determined by IHC staining, and fluorescence in situ hybridization was performed when stain-
ing of Her2 was scored as 2+ (i.e. uncertain amplification), to assess possible amplification of this gene. Samples 
were excluded from further analysis when tissues had unclear expression of ER, PR or Her2, no information on 
lymph-node status and/or adjuvant systemic chemotherapy, and/or poor quality of CMPK1 staining (defined as: 
heterogeneous staining between cores belonging to the same specimen and/or lack of triplicate staining due to 
lack of at least one core), resulting in a final number of 267 (EMC), 48 (RUMC), and 83 (CUH) tissues for data 
analysis, respectively. Out of a total of 398 samples included in the TMA, Clinical and histopathological features 
of these tissues are summarized in Table 1.
This study was approved by the Medical Ethics Committee of the EMC, The Netherlands (MEC 02.953) 
and was performed in accordance to the Code of Conduct of the Federation of Medical Scientific Societies in 
The Netherlands, and wherever possible we adhered to the Reporting Recommendations for Tumor Marker 
Prognostic Studies (REMARK)19. Informed consent was obtained from all patients.
Tissue micro-array. The TMAs were prepared using an ATA 27 (Beecher Instruments, Sun Prairie, WI, 
USA). For every tissue, a specialized breast pathologist marked the tumor area, from which three different 
cores (diameter: 0.6 mm) were taken as biological replicates and transferred in a TMA recipient block. Tissue 
cores of 0.6 mm were taken from each tissue paraffin block and transferred in triplicate into a TMA recipient 
block. Stained TMA slides were digitalized and analyzed using Slidepath software (Leica Microsystems, Solms, 
Germany).
IHC staining. Sections of 4 μ m of the three above mentioned TMAs were incubated for 1 hour at room tem-
perature with CMPK1 antibody at a dilution of 1:300 against the protein (mouse monoclonal, clone 1D7; Lifespan 
Bioscience, Seattle, WA, USA). Antigen retrieval was performed prior to antibody incubation by heating the slides 
for 40 min at 95 °C and washing with Dako antigen retrieval solution (pH = 6) (DakoCytomation, Carpinteria, 
CA, USA) when the slides were cooled down to room temperature. Staining was visualized by anti-mouse 
EnVision+ ® System-HRP (DAB) (DakoCytomation, Carpinteria, CA, USA). CMPK1 staining was separately 
scored in both percentage of positive invasive breast carcinoma cells and staining intensity by two independent 
observers. Six categories were scored for the percentage of positive invasive tumor cells: 0%, 1–10%, 11–25%, 
26–50%, 51–70%, and > 70%. All cores present on the three TMAs were scored by an experienced researcher 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:32027 | DOI: 10.1038/srep32027
in a blind manner. Staining score of triplicate cores were validated by a second experienced researcher, who was 
extensively trained by a specialized breast pathologist.
Data analysis. Differences between centers of origin were evaluated prior CMPK1 IHC staining analysis. 
Differences in patient menopausal status, tumor size, tumor differentiation and number of number of positive 
lymph nodes were assessed by χ 2 test, while Kruskal-Wallis test was performed to assess differences in patient age.
In order to derive a more accurate measurement of CMPK1 expression as measured by IHC, intensity and 
quantity categories were transformed into numerical values (Table S1) and a ‘histo-score’ (as reported in15) was 
calculated for both the cytoplasmic and nuclear staining components with the following formula:
− =Histo score intensity value x quantity value( ) ( )
Nuclear and cytoplasmic CMPK1 histo-score distributions were divided into four categories: 0–5, 6–10, 11–15, 
and 16–20 (Fig. 2A–D and Fig. S4A–D). Center of origin stratified univariate and multivariate Cox regression 
analyses were performed using Stata software (version 12.0). Clinical and histo-pathological characteristics 
included in Cox regression multivariate models were: age at diagnosis (categories: < 40, 41–55, 56–70, > 70), 
menopausal status (categories: premenopausal, postmenopausal), tumor size (categories: pT1, pT2 + pTx, 
pT3 + pT4), and tumor grade (Bloom-Richardson; categories: good, moderate, poor). Survival curves were plot-
ted and Log-rank test for trend was performed. In order to test whether nCMPK1 histo-score showed an asso-
ciation to chemotherapy treatment, we assessed whether a difference in nCMPK1 levels between chemotherapy 
treated and untreated patients existed by Mann-Whitney test. Previously reported MS data (ProteomeXchange 
identifier: PXD000260) of samples also included in the TMA were collected and Log10 CMPK1 intensity levels 
were compared with matching nuclear and cytoplasmic histo-scores. Spearman correlation analysis was per-
formed to test the association between CMPK1 IHC and MS levels. Kruskal-Wallis, χ 2 test, Log-rank test for 
trend, and Spearman correlation analyses were performed in GraphPad (version 5.1).
Affymetrix gene expression data of 60 samples that matched with the TNBC tissues on the TMA (deposited 
in GEO with dataset identifier: GSE2034) were collected and stratified according to nCMPK1 IHC stainings 
(histo-score categories: 0–5, 6–10, 11–15, 16–20). GSEA was performed on this set of samples to identify gene sets 
correlated with nCMPK1 IHC expression using a canonical pathway Molecular Signatures Database (MSigDB) 
(version 5.1)20. False discovery rates (FDRs) of enriched pathways were estimated based on 1,000 time permuta-
tion on defined phenotypes with fixed 149 seeds. Multiple probes assigned to the same gene were collapsed into 
single gene expression using the probes with the highest expression value for every tested sample. Heat-maps and 
violin plots were generated using Bioconductor (version 3.0) package ‘made4’ and ‘ggplot2’, respectively.
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